Ramatroban

• CAT Number: I000598
• CAS Number: 116649-85-5
• Molecular Formula: C21H21FN2O4S
• Molecular Weight: 416.5
• Purity: ≥95%
• Target: Prostaglandin Receptor
• Solubility: 10 mM in DMSO
• Storage: 2-8°C
• IUPAC Name: 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid
• InChI: InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
• InChIKey: LDXDSHIEDAPSSA-OAHLLOKOSA-N
• SMILES: C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O

Ramatroban (Cat No.: I000598) is a highly selective antagonist of thromboxane A2 (TxA2) with an impressive IC50 value of 14 nM. Additionally, it acts as a CRTH2 antagonist by inhibiting the binding of prostaglandin D2 (PGD2) with an IC50 of 113 nM. This dual functionality makes Ramatroban a valuable tool for researchers studying TxA2 and PGD2-mediated pathways, as well as potential therapeutic applications in various inflammatory and allergic conditions. For further information or specific inquiries regarding Ramatroban, please don’t hesitate to contact us.

Reference

1:Inverse agonism of SQ 29,548 and Ramatroban on Thromboxane A2 receptor. Chakraborty R, Bhullar RP, Dakshinamurti S, Hwa J, Chelikani P.PLoS One. 2014 Jan 23;9(1):e85937. doi: 10.1371/journal.pone.0085937. eCollection 2014. PMID: 24465800 Free PMC Article2:Asymmetric chemoenzymatic synthesis of ramatroban using lipases and oxidoreductases. Busto E, Gotor-Fernández V, Gotor V.J Org Chem. 2012 May 18;77(10):4842-8. doi: 10.1021/jo300552v. Epub 2012 May 1. PMID: 22515546 3:Prophylactic effects of the histamine H1 receptor antagonist epinastine and the dual thromboxane A2 receptor and chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist ramatroban on allergic rhinitis model in mice. Suzuki Y, Inoue T, Yamamoto A, Sugimoto Y.Biol Pharm Bull. 2011;34(4):507-10. PMID: 21467637 Free Article4:Successful treatment of eosinophilic otitis media using ramatroban: report of two cases. Wada T, Uemaetomari I, Murashita H, Tobita T, Tsuji S, Tabuchi K, Okubo H, Hara A.Auris Nasus Larynx. 2006 Dec;33(4):455-60. Epub 2006 Aug 8. PMID: 16899348 5:CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses. Sugimoto H, Shichijo M, Okano M, Bacon KB.Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. Epub 2005 Oct 27. PMID: 16256979 6:Isosteric ramatroban analogs: selective and potent CRTH-2 antagonists. Robarge MJ, Bom DC, Tumey LN, Varga N, Gleason E, Silver D, Song J, Murphy SM, Ekema G, Doucette C, Hanniford D, Palmer M, Pawlowski G, Danzig J, Loftus M, Hunady K, Sherf BA, Mays RW, Stricker-Krongrad A, Brunden KR, Harrington JJ, Bennani YL.Bioorg Med Chem Lett. 2005 Mar 15;15(6):1749-53. PMID: 15745833 7:Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. Ulven T, Kostenis E.J Med Chem. 2005 Feb 24;48(4):897-900. PMID: 15715457 8:Pharmacokinetic analysis of ramatroban using a recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference in Sprague-Dawley and Eisai hyperbilirubinemic rats. Moriwaki T, Yasui H, Yamamoto A.Pharm Res. 2004 Jun;21(6):1055-64. PMID: 15212172 9:Ramatroban (BAY u 3405): a novel dual antagonist of TXA2 receptor and CRTh2, a newly identified prostaglandin D2 receptor. Ishizuka T, Matsui T, Okamoto Y, Ohta A, Shichijo M.Cardiovasc Drug Rev. 2004 Summer;22(2):71-90. Review. PMID: 15179446 10:Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Kariyazono H, Nakamura K, Arima J, Ayukawa O, Onimaru S, Masuda H, Iguro Y, Majima HJ, Sakata R, Yamada K.Blood Coagul Fibrinolysis. 2004 Mar;15(2):157-67. PMID: 15091003